Company news

Amplia Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quarterly Activities and Cashflow Reports - Sep 2022 Qtr

October 27, 2022

AMP886 Activity in Acute Myeloid Leukemia

October 2, 2022

CEO Resignation

September 11, 2022

Amplia Receives $1.8m R&D Tax Incentive

August 30, 2022

CEO & Managing Director Presentation to AGM

August 25, 2022

First Patient Recruited to ACCENT Trial in Pancreatic Cancer

August 2, 2022

Quarterly Activities and Cashflow Reports - June 2022 Qtr

July 28, 2022

AMP945 Shows Efficacy in Model of Lung Fibrosis

June 1, 2022

Preliminary Final Report and Annual Report YE 31 March 2022

May 29, 2022

Amplia Receives Second Ethics Clearance for Phase 2 Trial

May 12, 2022

AMP945 Pre-IND Meeting Outcome

May 8, 2022

Quarterly Activities and Cashflow Reports - March 2022 Qtr

April 19, 2022

Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients

April 6, 2022

AMP945 Improves Survival in Human Pancreatic Cancer Model

February 16, 2022

Quarterly Activities and Cashflow Reports - Dec 2021 Qtr

January 23, 2022

Amplia Completes Manufacture of AMP945 for Planned Trials

January 12, 2022

Amplia Provides Updated Investor Presentation

December 15, 2021

Entitlement Offer Completed

December 10, 2021

Amplia Awarded $2.1M R&D Cash Flow Loan

December 2, 2021

App 4D and Financial Report Half Year ended 30 Sep 2021

November 24, 2021

Inhibition of FAK by AMP945 in Phase 1 Clinical Trial

November 16, 2021

Capital Raising Investor Presentation

November 7, 2021

Entitlement Offer Prospectus

November 7, 2021

Placement and Underwritten Entitlement Offer to Raise $12.4m

November 7, 2021

Quarterly Activities and Cashflow Reports - Sep 2021 Qtr

October 27, 2021

Amplia Receives $1.1m R&D Tax Incentive

October 13, 2021

New Garvan Publication Supports Amplia Phase 2 Design

September 29, 2021

Phase 2 Trial in First-Line Pancreatic Cancer Patients

September 14, 2021

AGM - Chief Executive Officers Presentatioin

August 27, 2021

Quarterly Activities and Cashflow Reports and Presentation

July 27, 2021

Results from Successful Phase 1 Clinical Trial of AMP945

July 20, 2021

Amplia and Garvan Enter Into Collaboration Agreement

June 27, 2021

AMP945 Improves Survival in Pacnreatic Cancer Model

June 1, 2021

App 4E - Preliminary Final Report YE 31 March 2021

May 31, 2021

Proposed issue of Securities - ATX

May 4, 2021

Amplia Announces $3.8m Share Placement

May 3, 2021

Preclinical Data Support Developmnt AMP945 Pancreatic Cancer

April 27, 2021

Quarterly Report and Shareholder Update

April 27, 2021

ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH

April 19, 2021

Amplia Completes Dosing in Phase 1 Clinical Study of AMP945

April 14, 2021

Amplia and Garvan Institute Enter Collaboration Agreement

March 17, 2021

Amplia Completes Single Dose Study of AMP945

March 16, 2021

Amplia Initiates Multiple Dose Study of AMP945

February 16, 2021

Investor Update - February 2021

February 10, 2021

Quarterly Activities and Cashflow Reports - Dec 2020 Qtr

January 27, 2021

Amplia Receives $0.53m R&D Tax Incentive

December 1, 2020

Appendix 4D and Financial Report Half Year Ended 30 Sep 2020

November 27, 2020

ATX - Sep 2020 Quarter Activities and Cashflow Reports

October 28, 2020

Response to ASX Price Query

October 20, 2020

First Human Dose in Phase 1 Clinical Trial of AMP945

October 8, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 37 decks. Every deck is listed under its year.